Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INO-5401 |
Synonyms | |
Therapy Description |
INO-5401 is a synthetic DNA immunotherapy that delivers plasmids to express three tumor associated antigens (WT1, PSMA (FOLH1), and TERT), which stimulates the immune system to attack cells expressing these antigens (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT114). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INO-5401 | INO5401|INO 5401 | INO-5401 is a synthetic DNA immunotherapy that delivers plasmids to express three tumor associated antigens (WT1, PSMA (FOLH1), and TERT), which stimulates the immune system to attack cells expressing these antigens (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT114). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04367675 | Phase I | INO-5401 INO-5401 + INO-9012 | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Recruiting | USA | 0 |